Dr. Phillip Frost, MD, is Chairman & Chief Executive Officer at OPKO Health, Inc., Chairman at Teva Pharmaceutical Industries Ltd., Chairman of the Investment Committee at Peregrine Ventures, Chairman at Ladenburg Thalmann & Co., Inc., Chairman at Ladenburg Thalmann Financial Services, Inc., Chairman at Temple Emanu-El, a Member at The Florida Council of 100, a Member at Frost Group LLC, and Chairman at Lachema as.
He is on the Board of Directors at Castle Brands, Inc., Mount Sinai Medical Center, University of Miami (Florida), Miami Jewish Home & Hospital for The Aged, Tel-Aviv University, Cocrystal Discovery, Inc., Fabrus, Inc., Morgan Solar, Inc., TransEnterix, Inc., Frost Gamma Investments Trust, and Smithsonian Institution.
Dr. Frost was previously employed as Chairman by Ideation Acquisition Corp., Chairman by PROLOR Biotech, Inc., Chairman & Chief Executive Officer by eXegenics, Inc., Chairman by IVAX Diagnostics, Inc., Co-Vice Chairman & Governor by American Stock Exchange LLC, Chairman & Chief Executive Officer by IVAX Corp., Chairman by Key Pharmaceuticals, Inc., Chairman-Dermatology Department by Mount Sinai Medical Center of Florida, Inc., Chairman by Whitman Education Group, Inc., Chairman & Chief Executive Officer by IVAX Pharmaceuticals, Inc., Chairman & Chief Executive Officer by Sorrento Therapeutics, Inc., General Partner & Investment Committee Member by Incentive Technological Incubator Ltd., a Trustee by The Scripps Research Institute, and Vice Chairman by North American Vaccine, Inc.
He also served on the board at BioZone Pharmaceuticals, Inc., SafeStitch Medical, Inc., Orthodontix, Inc., Cellular Technical Services Co., Inc., Continucare Corp., Northrop Grumman Corp., Protalix Biotherapeutics, Inc., Smithsonian Institution, and TransEnterix, Inc.
He received his undergraduate degree from the University of Pennsylvania and a doctorate degree from the Albert Einstein College of Medicine.